JPRN-UMIN000050335招募中Unknown
Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy. - Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients on dialysis Patients scheduled for less than 3 days of treatment with Tazobactam/Piperacillin Other patients deemed inappropriate by the attending physician
研究者
相似试验
进行中（未招募）
1 期
Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMAsepsis or septic shockMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-003496-36-FRHospices Civils de Lyon60
Unknown
2 期
Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial PneumoniaNosocomial PneumoniaNCT01796717Tianjin Medical University Cancer Institute and Hospital50
已完成
3 期
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas AeruginosaPseudomonas Aeruginosa InfectionNCT01577368Fundación Pública Andaluza para la gestión de la Investigación en Sevilla76
已完成
4 期
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous InfusionInfectious DiseaseNCT01198925University Hospital, Ghent14
进行中（未招募）
不适用
AObese patients with an infection treated by broad spectrum B-lactams.MedDRA version: 14.1Level: PTClassification code 10060945Term: Bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000652-18-BEHopital Erasme